R&D News | pharmaphorum

News

Acquisitive Ipsen builds again with $952m Albireo buy

French drugmaker Ipsen has continued a recent spate of deal-making with a $42-per-share offer to buy US biotech Albireo and its rare disease therapy Bylvay.

News

Chiesi expands rare disease portfolio with Amryt Pharma acqu...

Biopharma and healthcare group Chiesi Farmaceutici S.p.A.

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AstraZeneca bolts on blood pressure drug with CinCor takeove...

AstraZeneca has extended its cardiorenal pipeline with a $1.3 billion acquisition of CinCor Pharma, adding a late-stage blood pressure-lowering drug.

News

Takeda claims first phase 3 win in rare disease cTTP

Takeda has reported positive results from a phase 3 trial of its experimental therapy TAK-755 for ultra-rare disease congenital thrombotic thrombocytopenic purpura (cTTP), setting up regula

News

ACELYRIN acquires ValenzaBio, strengthens immunology positio...

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area,

News

UK partners with BioNTech on clinical trials of mRNA cancer ...

The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the

Acquisitive Ipsen builds again with $952m Albireo buy

Chiesi expands rare disease portfolio with Amryt Pharma acqu...

AstraZeneca bolts on blood pressure drug with CinCor takeove...

Takeda claims first phase 3 win in rare disease cTTP

ACELYRIN acquires ValenzaBio, strengthens immunology positio...

UK partners with BioNTech on clinical trials of mRNA cancer ...

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks